Johnson & Johnson dividend and legal outlook, shares in focus for S&P 500 investors

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 07:40.

Johnson & Johnson (US4781601046) enters the new week with investors weighing a crucial talc litigation timetable alongside its record of steady dividends. As one of the largest healthcare names in the S&P 500 and on the NYSE, the stock remains a global portfolio staple, as recent market commentary from major brokers shows.

What Reuters and filings highlight

Johnson & Johnson disclosed in April 2024 that a US judge set a July 19, 2024 hearing on its latest proposed plan to resolve talc-related claims through a prepackaged bankruptcy of its consumer-focused subsidiary, according to a detailed Reuters report on the talc settlement strategy. The company has earmarked up to 8.9 billion USD over 25 years for these liabilities under the proposed plan, illustrating the financial scale of the litigation overhang.

In parallel, Johnson & Johnson continues a long-standing pattern of dividend payments, having raised its quarterly dividend to 1.24 USD per share in April 2024 with an ex-dividend date in late May, as set out in its official dividend declaration and board resolution. That increase kept the company in the group of long-term US dividend growers, a feature many income-focused investors in North America and Europe follow closely.

Analyst stance and sector comparison

Analysts still tend to benchmark Johnson & Johnson against diversified healthcare peers such as Pfizer and Merck when assessing litigation risk versus cash-generation capacity, with several houses emphasizing the strength of its medical devices and pharmaceutical pipeline. A recent consensus overview compiled by MarketScreener shows a predominant Buy or Outperform stance from a majority of covering analysts, although target prices vary depending on individual assumptions for talc cash outflows and US pricing dynamics.

According to a late-June 2024 note summarized by MarketWatch analyst estimates for Johnson & Johnson, the average 12-month price target embeds mid-single-digit upside from recent trading levels, while several research houses highlight a relatively defensive earnings profile compared with the broader S&P 500. For many institutional investors, the key variable remains the speed and final cost of settling talc cases without jeopardizing the dividend policy.

The product behind the cash flows

Johnson & Johnson today generates most of its sales from pharmaceuticals and medical technology after the 2023 spin-off of its consumer health unit Kenvue, with blockbuster drugs such as Stelara for autoimmune diseases and Darzalex in oncology among the key earnings drivers. Its MedTech division supplies surgical instruments, orthopedics and cardiovascular solutions used daily in hospitals worldwide.

Where the stock trades today

Johnson & Johnson shares most recently traded around 145 USD on the NYSE, based on closing data from late June 2026, reflecting a large-cap healthcare valuation that many investors still view primarily through the lens of reliable dividends and manageable legal risk.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.